ESPE Abstracts (2021) 94 P1-2

1Department of Pediatric Endocrinology and Diabetes, Marmara University, School of Medicine, Istanbul, Turkey; 2Department of Pediatric Genetics, Umraniye Research and Training Hospital, University of Health Sciences, Istanbul, Turkey; 3Department of Pediatric Endocrinology, Haseki Training and Research Hospital, Istanbul, Turkey; 4Department of Pediatric Endocrinology and Diabetes, Kanuni Sultan Suleyman Research and Training Hospital, University of Health Sciences, Istanbul, Turkey; 5Department of Pediatric Endocrinology and Diabetes, Behcet Uz Education and Research Hospital, Izmir, Turkey; 6Department of Pediatrics, Duzce University, School of Medicine, Bolu, Turkey; 7Department of Pediatric Endocrinology and Diabetes, Ataturk University, School of Medicine, Erzurum, Turkey; 8Department of Pediatric Endocrinology and Diabetes, Istanbul Medeniyet University Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Turkey; 9Department of Pediatric Endocrinology, Kartal Training and Research Hospital, Istanbul, Turkey; 10Department of Pediatric Endocrinology, Aydin Adnan Menderes University, School of Medicine, Aydin, Turkey; 11Department of Pediatric Endocrinology and Diabetes, Kosuyolu İstanbul Medipol Hospital, Istanbul, Turkey; 12Department of Pediatric Endocrinology and Diabetes, Selcuk University, School of Medicine, Konya, Turkey; 13Department of Pediatric Endocrinology and Diabetes, Dokuz Eylul University, School of Medicine, Izmir, Turkey; 14Department of Pediatric Endocrinology and Diabetes, Onsekiz Mart University, School of Medicine, Canakkale, Turkey; 15Department of Pediatric Endocrinology and Diabetes, Umraniye Research and Training Hospital, University of Health Sciences, Istanbul, Turkey; 16Department of Pediatric Endocrinology and Diabetes, Derince Research and Training Hospital, Kocaeli, Turkey; 17Department of Pediatrics, Gungoren Hospital, Istanbul, Turkey


Background: Primary adrenal insufficiency other than congenital adrenal hyperplasia (non-CAH PAI) is very uncommon in children but associated with a variety of molecular defects. Biosynthesis of adrenocortical hormones is reduced although the relation of steroid profiles with underlying molecular etiology is not yet studied.

Objective: Investigation of clinical and steroid hormone profiles of a multicenter cohort of children with non-CAH PAI.

Design: Patients with CAH, adrenoleukodystrophy, autoimmune adrenal insufficiency or obvious syndromic PAI on clinical and biochemical assessment were excluded. Genetic analysis was performed using either targeted gene panel or whole-exome sequencing. Plasma adrenal steroids were quantified by liquid chromatography-mass spectrometry and compared to that of controls.

Setting: Sixteen tertiary pediatric endocrinology clinics.

Patients: Forty-one children (19 females, median age: 3 months, range: 0-8 years) with non-CAH PAI of unknown etiology.

Results: A genetic diagnosis was obtained in 29 (68%) patients by targeted gene panel. Further molecular diagnosis could not be achieved by WES. The range of etiologies was: MC2R (n = 6), StAR (n = 6), NNT (n = 3), NR0B1 (n = 3), CYP11A1 (n = 2), MRAP (n = 2), SGPL1 (n = 2), ABCD1 (n = 1), AIRE (n = 1), AAAS (n = 1), HSD3B2 (n = 1). Steroid profiling demonstrated low levels in all adrenocortical steroid hormones irrespective of age and not varied among the genetic etiologies except two patients with new-onset symptoms of PAI due to homozygous c.518T>A(p.Leu173Gln) SGPL1, and hemizygous c.1772G>T(p.Arg591Leu) ABCD1 defects, and another patient with non-classic non-CAH PAI due to homozygous c.1351C>T (p.Arg451Trp) variant in CYP11A1. Compared to age-matched healthy control group in whom steroid hormone concentrations are physiologically low, the patient group had even lower steroid concentrations, most significantly in cortisone, cortisol, and corticosterone (P < 0.0001, area under the ROC curve: 0.96, 0.88, 0.87, respectively). Plasma cortisol<4 ng/ml, cortisone<11 ng/ml, and corticosterone<0.11 ng/ml had >95% specificity to segregate non-CAH PAI patients compared to control groups.

Conclusion: Adrenocortical hormone profiles are highly sensitive for the diagnosis of non-CAH PAI, while, in contrast to CAH, they are unlikely to point out a specific molecular diagnosis. Targeted gene panel sequencing is an undisputed optimal approach in the molecular diagnosis of non-CAH PAI with low cost and high efficacy, while little additional benefit is expected from whole-exome sequencing. Further progress can be made, mainly by more collaboration and exchanging knowledge for delineation of rare causes of primary adrenal insufficiency.

Volume 94

59th Annual ESPE (ESPE 2021 Online)

Online,
22 Sep 2021 - 26 Sep 2021

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.